Benzinga | Jan 19, 2022 12:50PM EST

AstraZeneca Rolls Out "Unprecedented' Three Year Survival Data For Imfinzi/Treme Combo In Liver Cancer

A combination of tremelimumab and AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) extended the lives of newly diagnosed patients with unresectable hepatocellular carcinoma compared with sorafenib.

* The risk of death was 22% lower for the Imfinzi + tremelimumab combo versus over sorafenib, a standard-of-care multi-kinase inhibitor.

* For the Phase 3 HIMALAYA trial in front-line liver cancer, the Company used a single dose of tremelimumab 300mg added to Imfinzi 1500mg followed by Imfinzi every four weeks (STRIDE regime).

* Related: AstraZeneca's Imfinzi / Tremelimumab Combo Regime Shows Survival Benefit In Lung Cancer Settings.

* Patients lived a median of 16.4 months on the Infimzi therapy versus 13.8 months on sorafenib.

* While the two-year survival rates were similar at around 40%, the three-year number was 30.7% for the Infimzi/ treme combo versus 24.7% for Imfinzi monotherapy.

* On the safety side, AstraZeneca reported that more patients treated with the STRIDE regimen experienced Grade 3 or 4 treatment-related adverse events than those who got Imfinizi monotherapy -- 25.8% versus 12.9% -- but noted it's still lower than the 36.9% rate for sorafenib.

* Price Action: AZN shares are down 0.32% at $59.65 during the market session on the last check Wednesday.